MELBOURNE, Australia, May 21, 2025 /PRNewswire/ -- Air Liquide has entered into an agreement with Manildra Group to build a new food and beverage grade carbon dioxide (COâ‚‚) plant in Bomaderry, New South Wales. This facility will capture and purify the biogenic COâ‚‚ produced naturally by Shoalhaven Starches from fermentation of wheat, and supply the purified COâ‚‚ product to Australian industries.
Air Liquide will build, own and operate a new COâ‚‚ plant with a production capacity of over 90,000 tonnes per year of food and beverage grade COâ‚‚, which would make it the largest food and beverage quality COâ‚‚ plant in Australia. Construction of the new Air Liquide facility is planned to commence in the second half of 2025, subject to regulatory approvals, and it is anticipated to be operational in 2027.
The biogenic COâ‚‚ produced naturally from fermentation of wheat at Manildra Group's Shoalhaven Starches site provides abiogenic COâ‚‚ product offering to meet the growing needs of the food and beverage industry and other applications.
High quality food and beverage grade COâ‚‚ serves the needs of Australian businesses in a broad range of industries where quality and reliability of supply are a necessity. This includes food, beverages, water treatment, desalination, hospitality, manufacturing and medical industries.
Tim Kehoe, Managing Director of Air Liquide Pacific said: "To address the critical need for increased supply and improved reliability in domestic COâ‚‚, Air Liquide has partnered with Manildra to provide a biogenic CO2 solution. Air Liquide's new COâ‚‚ plant will boost local COâ‚‚ supply and demonstrates our commitment to supporting the growth needs of Australian industries well into the future."
John Honan, Managing Director of Manildra Group said: "Through our partnership with Air Liquide, we're delivering 100% Australian, food-grade CO₂ for essential local industries – part of our broader commitment to closing the loop in our advanced manufacturing process. Together we're building a long-term solution to strengthen local supply chains with high-quality, biogenic CO₂."
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Air Liquide partners with Manildra Group to build Australia's largest biogenic CO₂ plant, strengthening national supply
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
